Aralez Pharmaceuticals Inc. (ARLZ) Stock Rating Reaffirmed by Chardan Capital
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research note issued to investors on Wednesday. They currently have a $10.00 price target on the stock. Chardan Capital’s target price points to a potential upside of 102.02% from the company’s current price.
Separately, Guggenheim reissued a “buy” rating and issued a $12.00 price objective on shares of Aralez Pharmaceuticals in a research note on Monday.
Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) traded down 3.32% during mid-day trading on Wednesday, hitting $4.95. 457,471 shares of the company’s stock traded hands. The firm has a 50-day moving average of $5.29 and a 200 day moving average of $4.20. The company’s market cap is $322.94 million. Aralez Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $8.59.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/aralez-pharmaceuticals-inc-arlz-stock-rating-reaffirmed-by-chardan-capital.html
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. Aralez Pharmaceuticals’s revenue for the quarter was up 142.3% compared to the same quarter last year. Equities research analysts predict that Aralez Pharmaceuticals will post ($1.06) EPS for the current year.
In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $5.82, for a total transaction of $873,000.00. Following the sale, the director now owns 669,094 shares of the company’s stock, valued at $3,894,127.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 6.77% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Bank of Montreal Can bought a new stake in Aralez Pharmaceuticals during the second quarter worth $100,000. Advisor Group Inc. bought a new stake in Aralez Pharmaceuticals during the second quarter worth $118,000. Knott David M bought a new stake in Aralez Pharmaceuticals during the second quarter worth $124,000. Alpine Partners VI LLC bought a new stake in Aralez Pharmaceuticals during the second quarter worth $133,000. Finally, LMR Partners LLP bought a new stake in Aralez Pharmaceuticals during the second quarter worth $145,000. 49.63% of the stock is currently owned by hedge funds and other institutional investors.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.